About Us

InterveXion is a privately-held clinical-stage biopharmaceutical company developing novel products for the treatment of addiction disorders.  Our lead clinical asset is IXT-m200, a monoclonal antibody directed against methamphetamine, which acts by re-partitioning methamphetamine away from its sites of action in the CNS.  IXT-m200 has received US FDA Fast Track Designation, and is being studied in an ongoing Phase 2 proof-of-concept study (STAMPOUT; NCT03336866).  We are also developing a novel vaccine (IXT-v100) against methamphetamine, which is in Preclinical Development.